Ocular neovascularization

Shen J, Samul R, Silva RL et al (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13 (3) 225-234... 

In addition to the work presented here, several alternative viral-vectored approaches have been reported recently. An adeno-associated viral vector (AAV) encoding the soluble VEGF receptor 1, sFlt-1, shows promise for long-term inhibition of two types of ocular neovascularization (Lai et al., 2002). This vector, when injected into the anterior chamber, resulted in expression in both the corneal endothelium and iris pigment epithelium and reduced corneal NV by 36%. Subretinal injection of the same vector reduced choroidal NV subsequent to laser lesions around the optic nerve. These results suggest that a secretable factor expressed in one or more transduced cell populations can be elfective in the control of ocular NV occurring in a disparate cell population. 

Dorrell, M., Uusitalo-Jarvinen, H., Aguilar, E., Friedlander, M. (2007a). Ocular neovascularization basic mechanisms and therapeutic advances. Survey Ophthalmol. 52 (Suppl. 1) S3-19. 

Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization promises and potential problems. JAMA 2005 293 1509. 

Gonzales CR,VEGE Inhibition Smdy in Ocular Neovascularization (Vl.S.l.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium an exploratory analysis. Retina 2005 25 815. 

Gragoudas ES,Adamis AP, Cunningham ET Jr, et al. Pegaptamb for neovascular age-related macular degeneration. VEGF Inhibition Smdy in Ocular Neovascularization Climcal Trial Group. N Engl J Med 2004 351 2805. 

In addition to targeting tumor neovasculature, we also studied the RGD ligand targeted nanoparticle for targeting ocular neovasculature tissues [5]. The antiangiogenesis efficacy observed in ocular neovascularization mcxlels further demonstrated this... 

Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 1997 151 13-23. 

Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997 13 37-50. 

Neely K, Gardner T. Ocular neovascularization—clarifying complex interactions. Am J Pathol 1998 153 665-670. 

Reich S, Fosnot J, Kuroki A, et al. Small interfering RNA targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vision 2003 9 210-216. 

Reich S, Bennett J. Gene therapy for ocular neovascularization a cure in sight. Curr Opin Genet Dev 2003 13 317-322. 

Nambu H, Nambu R, Oshima Y, et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 2004 11(10) 865—873. 

Ophthalmology ocular neovascularizations - age related macular degeneration - corneal neovascularization... 

Chapman, J. A., Beckey, C. (2006). Pegaptanib a novel approach to ocular neovascularization. Ann Pharmacother 40, 1322-1326. 

---